Application of Alive Collagen supplement in genitourinary menopausal syndrome
- Authors: Bakhtiyarov K.R.1, Kuzmina P.I.1, Cherkashina A.V.1
-
Affiliations:
- I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
- Issue: No 1 (2024)
- Pages: 123-128
- Section: Exchange of Experience
- URL: https://journals.eco-vector.com/0300-9092/article/view/628887
- DOI: https://doi.org/10.18565/aig.2023.289
- ID: 628887
Cite item
Open Access
Access granted
Abstract
Objective: To evaluate the efficacy and safety of Alive Collagen in postmenopausal women with genitourinary menopausal syndrome (GMS).
Materials and methods: This was a single-center, uncontrolled before-after study. Twenty-five women aged 50–68 years (mean age is 59.44±5.39 years) diagnosed with postmenopausal atrophic vaginitis were examined at the Family Clinic from April to June 2023. The efficacy of taking Alive Collagen at a dosage of 15 g/day for 12 weeks was evaluated. The analysis was carried out using a questionnaire with calculation of the Female Sexual Function Index (FSFI) and visual analog scale developed by R. Nappi.
Results: The postmenopausal period lasted 7±2.40 years, the duration of GMS symptoms ranged from 2 to 10 years (mean period is 5.44±2.63 years). In 12 weeks after taking Alive Collagen, the women noticed a decrease in the symptoms of GMS, namely, itching, burning, and vaginal dryness; a decrease in the severity of dyspareunia was also revealed. FSFI increased from 15.36±4.33 before therapy to 21.58±3.94 after collagen supplementation for 12 weeks. No adverse side effects were detected.
Conclusion: The patients suffering from various symptoms of GMS and having contraindications to menopausal hormone therapy can have a possible alternative to improve their quality of life by taking Alive Collagen supplement at a dose of 15 g/day 30 minutes before meals for 12 weeks.
Full Text
About the authors
Kamil R. Bakhtiyarov
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Author for correspondence.
Email: doctorbah@mail.ru
ORCID iD: 0000-0001-7114-4050
Dr. Med. Sci., Professor, Sechenov First Moscow State Medical University
Russian Federation, 119991, Moscow, Trubetskaya str., 8-2Polina I. Kuzmina
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Email: kuzmina_p_i@student.sechenov.ru
ORCID iD: 0009-0004-0098-1774
Student of the Institute of Clinical Medicine named after N.V. Sklifosovsky
Russian Federation, 119991, Moscow, Trubetskaya str., 8-2Anna V. Cherkashina
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Email: cherkashina_a_v@student.sechenov.ru
ORCID iD: 0000-0002-3840-1948
Student of the Institute of Clinical Medicine named after N.V. Sklifosovsky
Russian Federation, 119991, Moscow, Trubetskaya str., 8-2References
- Kagan R., Kellogg-Spadt S., Parish S.J. Practical treatment considerations in the management of genitourinary syndrome of menopause. Drugs Aging. 2019; 36(10): 897-908. https://dx.doi.org/10.1007/s40266-019-00700-w.
- El Khoudary S.R., Greendale G., Crawford S.L., Avis N.E., Brooks M.M., Thurston R.C. et al. The menopause transition and women's health at midlife: a progress report from the Study of Women's Health Across the Nation (SWAN). Menopause. 2019; 26(10): 1213-27. https://dx.doi.org/10.1097/GME.0000000000001424.
- Angelou K., Grigoriadis T., Diakosavvas M., Zacharakis D., Athanasiou S. The genitourinary syndrome of menopause: an overview of the recent data. Cureus. 2020; 12(4): e7586. https://dx.doi.org/10.7759/cureus.7586.
- Cagnacci A., Xholli A., Sclauzero M., Venier M., Palma F., Gambacciani M.; Writing Group of the ANGEL study. Vaginal atrophy across the menopausal age: results from the ANGEL study. Climacteric. 2019; 22(1): 85-9. https://dx.doi.org/10.1080/13697137.2018.1529748.
- Isaza P.G. Use of growth factors for vulvo/vaginal bio-stimulation. Surg. Technol. Int. 2019; 34: 269-73.
- Kasap B., Kasap Ş., Vatansever S., Kendirci R., Yılmaz O., Çalışır M. et al. Effects of adipose and bone marrow-derived mesenchymal stem cells on vaginal atrophy in a rat menopause model. Gene. 2019; 711: 143937. https://dx.doi.org/10.1016/j.gene.2019.06.027.
- Пищевой Живой Коллаген торговой марки Colla Gen. [Food Alive Collagen branded by Colla Gen (in Russian)]. https://collagen-pmt.ru/ pishchevoy-kollagen/
- Rosen R., Brown C., Heiman J., Leiblum S., Meston C., Shabsigh R. et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J. Sex Marital Ther. 2000; 26(2): 191-208. https://dx.doi.org/10.1080/ 009262300278597.
- Министерство здравоохранения Российской Федерации. Клинические рекомендации «Менопауза и климактерическое состояние у женщины». 2021. [Ministry of Health of the Russian Federation. Clinical guidelines "Menopause and menopause in a woman." 2021. (in Russian)].
- Nappi R.E., Palacios S., Bruyniks N., Particco M., Panay N.; EVES study investigators. The burden of vulvovaginal atrophy on women's daily living: implications on quality of life from a face-to-face real-life survey. Menopause. 2019; 26(5): 485-91. https://dx.doi.org/10.1097/GME.0000000000001260.
- Балан В.Е., Краснопольская К.В., Оразов М.Р., Токтар Л.Р., Тихомирова Е.В. Коллагенотерапия пациенток с генитоуринарным менопаузальным синдромом – новая возможность в арсенале врача. Российский вестник акушера-гинеколога. 2020; 20(4): 65 75. [Balan V.E., Krasnopol’skaya K.V., Orazov M.R., Toktar L.R., Tikhomirova E.V. Collagenotherapy for patients with genitourinary menopausal syndrome is a new opportunity in the doctor’s arsenal. Russian Bulletin of Obstetrician-Gynecologist. 2020; 20(4): 65-75. (in Russian)]. https:// dx.doi.org/10.17116/rosakush20202004165.
Supplementary files
